Gene Therapy: Is There Oversight For Patient Safety: Hearing Before The Committee On Health, Education, Labor, And Pensions, U.s. Senate

by Bill Frist (Editor)

Paul Gelsinger, father of Jesse Gelsinger, participant in gene therapy; Eric Kast, Norman, OK, on behalf of the Cystic Fibrosis Fdn.; Amy Patterson, Dir., Office of Biotech. Activities, NIH; Jay Siegel, Dir., Office of Therapeutic Res. & Review, FDA; Inder Verma, Prof., Molecular Biology, Lab. of Genetics, the Salk Inst., La Jolla, CA; Leroy Walters, Dir., Kennedy Inst. of Ethics, Georgetown Univ.; H. Stewart Parker, president & CEO, Targeted Genetics Corp., Seattle, WA, on behalf of the Biotech. Industry Org.; Introgen Therapeutics, Inc.; & Vera Hassner Sharav, pres. & cofounder & Adil E. Shamoo, v.p. & cofounder, Citizens for Responsible Care & Research.

126 pages, Paperback

First published April 1, 2000